Notification of Dilution of Voting Rights

London: Friday, November 27, 2020:   Hutchison China MediTech Limited (" Chi-Med ") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (" CK Hutchison ") shareholding^[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of Chi-Med ("Shares"). 

Each American Depositary Share ("ADS") represents five Shares.  As announced on November 17, 2020, Chi-Med issued a total of 16,666,670 Shares (equivalent to 3,333,334 ADSs) to Canada Pension Plan Investment Board.  Chi-Med was notified on November 26 , 2020 that this issuance diluted CK Hutchison's holding^[1] to 45.69 per cent of the total number of voting rights of Chi-Med.  The date on which the notification threshold was crossed was November 26, 2020.

^[1] Held through CK Hutchison's indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

CONTACTS